(Aviation-NewsWire.Com, October 02, 2018 ) Betaxolol is a selective beta1 receptor blocker, which is used in the treatment of hypertension and glaucoma. The molecular formula of betaxolol is C18H29NO3. As this compound is selective for beta1 receptors, systemic side effects associated with these are less, as compared to the non-selective beta-blockers. Moreover, betaxolol shows greater affinity for beta1 receptors than metoprolol. Apart from the effects of betaxolol on heart, it also reduces the pressure within the eye. It is achieved through the reduction in production of liquid within the eye. Pressure reduction within the eye reduces the risk of damage to the optic nerve and loss of vision in patients with elevated intraocular pressure due to glaucoma.
Increasing prevalence of diabetes and growing geriatric population are major factors causing the condition of glaucoma, which will, in turn drive growth of betaxolol market. Moreover, enhanced patient awareness programs leads to early diagnosis of diseases such as hypertension and glaucoma followed by treatment, which is further expected to drive growth of betaxolol market
However, patients suffering from sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure cannot use this medicine. This is one of the factors restraining growth of the market.
Key Developments in Betaxolol Market
Key players are adopting various strategies such as mergers, acquisitions, new product launches, expansions, collaborations, partnerships, approvals, and joint ventures to retain its position in the betaxolol market. On June 7, 2018, Bayer completed the acquisition of Monsanto, an agrochemical and agricultural biotechnology corporation.
Moreover, on June 1, 2018, Bayer signed a five-year collaboration agreement with the University of Texas MD Anderson Cancer Center to accelerate the development of novel targeted treatments based on patient or tumor characteristics for, which current therapies have not shown satisfactory clinical efficacy.
On April 12, 2018, GSK signed a strategic agreement with Orchard Therapeutics to transfer its portfolio of approved and investigational rare disease gene therapies to Orchard, securing the continued development of the programs and access for patients.
Some of the major players operating in the betaxolol market include Pfizer Inc., Bayer Healthcare Pharmaceuticals, GlaxoSmithKline Plc., Merck and Company Inc., Syneron Medical Ltd, and Valeant Pharmaceuticals International among others.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Industry resource center today to browse our selection of 600+ complimentary Industry magazines, white papers, webinars, podcasts, and more. Get popular titles including: